文献速递类风湿关节炎

MIDORA试验:一项评估达佐达利贝治疗类风湿关节炎疗效与安全性的II期、随机、双盲、安慰剂对照、机制探索与剂量优化研究

The MIDORA trial: a phase II, randomised, double-blind, placebo-controlled, mechanistic insight and dosage optimisation study of the efficacy and safety of dazodalibep in patients with rheumatoid arthritis.
PubMed 文献 · RMD Open · 2023-01-01

MIDORA试验纳入78例对甲氨蝶呤、其他传统改善病情抗风湿药或TNF-α抑制剂应答不足且未接受过B细胞清除治疗的活动中重度类风湿关节炎成人患者,随机均分至5组接受不同剂量方案达佐达利贝或安慰剂静脉输注。第113天所有达佐达利贝组DAS28-CRP较基线下降均显著大于安慰剂组,第309天仍可见显著下降;不良事件分布总体均衡,4例严重不良事件经研究者判定与研究药物无关。

要点

  • 第113天所有达佐达利贝组DAS28-CRP较基线下降均显著大于安慰剂组。
  • 第309天所有达佐达利贝组仍观察到DAS28-CRP显著下降。
  • 不良事件分布总体均衡,4例严重不良事件经研究者判定与研究药物无关。

核心结论

  • 所有剂量方案的达佐达利贝治疗在第113天较安慰剂显著降低DAS28-CRP。
  • 安全性数据提示可接受的安全性和耐受性特征。
  • 第113天的治疗效应及达佐达利贝停用后反应持续时间延长支持使用更长的给药间隔。

研究设计与样本

  • II期、随机、双盲、安慰剂对照、机制探索与剂量优化研究(MIDORA试验)。
  • 纳入成人中重度活动性类风湿关节炎患者,血清类风湿因子和/或抗瓜氨酸化蛋白抗体阳性,对甲氨蝶呤、其他传统改善病情抗风湿药或TNF-α抑制剂应答不足,且未接受过B细胞清除治疗。
  • 合格参与者随机均分至5组接受达佐达利贝或安慰剂静脉输注。
  • 主要终点为第113天DAS28-CRP较基线的变化,随访至第309天。
  • 共随机78例合格参与者。

主要发现

  • 第113天DAS28-CRP较基线变化(最小二乘均值±标准误)在所有达佐达利贝组为-1.83±0.28至-1.90±0.27,显著大于安慰剂组的-1.06±0.26(p<0.05)。
  • 第309天所有达佐达利贝组仍观察到DAS28-CRP显著下降。
  • 不良事件分布总体均衡:达佐达利贝组74%,安慰剂组63%。
  • 4例严重不良事件经研究者判定与研究药物无关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the safety, efficacy and response duration of four different dosing regimens of dazodalibep (DAZ), a non-antibody biological antagonist of CD40L, in patients with rheumatoid arthritis (RA). METHODS: This double-blind study included adult patients with moderate-to-severe active RA with a positive test for serum rheumatoid factor and/or anticitrullinated protein antibodies, an inadequate response to methotrexate, other conventional disease-modifying antirheumatic drugs or tumour necrosis factor-α inhibitors, and no prior treatment with B-cell depleting agents. Eligible participants were randomised equally to five groups receiving intravenous infusions of DAZ or placebo. The primary endpoint was the change from baseline in the Disease Activity Score-28 with C reactive protein (DAS28-CRP) at day 113. Participants were followed through day 309. RESULTS: The study randomised 78 eligible participants. The change from baseline in DAS28-CRP (least squares means±SE) at day 113 was significantly greater for all DAZ groups (-1.83±0.28 to -1.90±0.27; p<0.05) relative to PBO (-1.06±0.26); significant reductions in DAS28-CRP were also observed for all DAZ groups at day 309. The distribution of adverse events was generally balanced among DAZ and PBO groups (74% and 63%, respectively). There were four serious adverse events deemed by investigators to be unrelated to study medication. CONCLUSIONS: DAZ treatment for all dosage regimens significantly reduced DAS28-CRP at day 113 relative to PBO. The safety data suggest an acceptable safety and tolerability profile. Treatment effects at day 113 and the prolonged duration of responses after DAZ cessation support the use of longer dosing intervals. TRIAL REGISTRATION NUMBER: NCT04163991.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Kivitz A, Wang L, Alevizos I, et al. The MIDORA trial: a phase II, randomised, double-blind, placebo-controlled, mechanistic insight and dosage optimisation study of the efficacy and safety of dazodalibep in patients with rheumatoid arthritis. RMD Open. 2023. PMID: 37541743. doi:10.1136/rmdopen-2023-003317

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。